12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GS-9973: Interim Phase II data

Interim data from 78 evaluable patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL) in the single-arm, open-label, U.S. Phase II Study 102 showed that twice-daily 800 mg oral GS-9973 was well tolerated. Reversible grade 3/4 transaminase elevations occurred in 9 patients. In 29 evaluable...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >